In vitro testing of newer cephalosporins (author's transl)

The spectrum of activity of the newer cephalosporins is considerably wider and includes a number of gram-negative bacteria. Test results using cephalothin as 'class disc' of a class of antibiotics is therefore no longer valid for the newer members. Like cefazoline, all of the above-mention...

Full description

Saved in:
Bibliographic Details
Published in:Infection 1979, Vol.7 Suppl 2, p.S225
Main Authors: Linzenmeier, G, Rosenthal, E
Format: Article
Language:ger
Subjects:
Cefamandole - pharmacology
Cefazolin - pharmacology
Cefoxitin - pharmacology
Cephalosporins - pharmacology
Cephalothin - pharmacology
Drug Resistance, Microbial
In Vitro Techniques
Microbial Sensitivity Tests
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue
container_start_page S225
container_title Infection
container_volume 7 Suppl 2
creator Linzenmeier, G
Rosenthal, E
description The spectrum of activity of the newer cephalosporins is considerably wider and includes a number of gram-negative bacteria. Test results using cephalothin as 'class disc' of a class of antibiotics is therefore no longer valid for the newer members. Like cefazoline, all of the above-mentioned antibiotics are more effective against Escherichia coli. Cefuroxin and cefoxitin also display increased effectiveness against Klebsiella, as do cefoxitin against Serratia and indolpositive Proteus species, and cefamandole and cefuroxime against Enterobacter. Cefotaxim is superior to all other agents, as was also demonstrated in our own inhibition zone tests; in addition cefotaxim is effective against Pseudomonas aeruginosa. Since the various pathogens do not exhibit a uniform pattern of resistance to these antibiotics, the four new agents should for the time being be tested independently of cephalothin and cefazoline.
format article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_437897</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>437897</sourcerecordid><originalsourceid>FETCH-pubmed_primary_4378973</originalsourceid><addsrcrecordid>eNpjYeA0MDYw0LUwNDLjYOAqLs4yMDAwtTQxZ2dgMzE2t7A052Sw8sxTKMssKcpXKEktLsnMS1fIT1PISy1PLVJITi3ISMzJLy7IL8rMK1bQSCwtycgvUi9WKClKzCvO0eRhYE1LzClO5YXS3Awybq4hzh66BaVJuakp8QVFmbmJRZXxEKuMCUgDAEjuMxA</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>In vitro testing of newer cephalosporins (author's transl)</title><source>Springer Archives (Through 1996)</source><creator>Linzenmeier, G ; Rosenthal, E</creator><creatorcontrib>Linzenmeier, G ; Rosenthal, E</creatorcontrib><description>The spectrum of activity of the newer cephalosporins is considerably wider and includes a number of gram-negative bacteria. Test results using cephalothin as 'class disc' of a class of antibiotics is therefore no longer valid for the newer members. Like cefazoline, all of the above-mentioned antibiotics are more effective against Escherichia coli. Cefuroxin and cefoxitin also display increased effectiveness against Klebsiella, as do cefoxitin against Serratia and indolpositive Proteus species, and cefamandole and cefuroxime against Enterobacter. Cefotaxim is superior to all other agents, as was also demonstrated in our own inhibition zone tests; in addition cefotaxim is effective against Pseudomonas aeruginosa. Since the various pathogens do not exhibit a uniform pattern of resistance to these antibiotics, the four new agents should for the time being be tested independently of cephalothin and cefazoline.</description><identifier>ISSN: 0300-8126</identifier><identifier>PMID: 437897</identifier><language>ger</language><publisher>Germany</publisher><subject>Cefamandole - pharmacology ; Cefazolin - pharmacology ; Cefoxitin - pharmacology ; Cephalosporins - pharmacology ; Cephalothin - pharmacology ; Drug Resistance, Microbial ; In Vitro Techniques ; Microbial Sensitivity Tests</subject><ispartof>Infection, 1979, Vol.7 Suppl 2, p.S225</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/437897$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Linzenmeier, G</creatorcontrib><creatorcontrib>Rosenthal, E</creatorcontrib><title>In vitro testing of newer cephalosporins (author's transl)</title><title>Infection</title><addtitle>Infection</addtitle><description>The spectrum of activity of the newer cephalosporins is considerably wider and includes a number of gram-negative bacteria. Test results using cephalothin as 'class disc' of a class of antibiotics is therefore no longer valid for the newer members. Like cefazoline, all of the above-mentioned antibiotics are more effective against Escherichia coli. Cefuroxin and cefoxitin also display increased effectiveness against Klebsiella, as do cefoxitin against Serratia and indolpositive Proteus species, and cefamandole and cefuroxime against Enterobacter. Cefotaxim is superior to all other agents, as was also demonstrated in our own inhibition zone tests; in addition cefotaxim is effective against Pseudomonas aeruginosa. Since the various pathogens do not exhibit a uniform pattern of resistance to these antibiotics, the four new agents should for the time being be tested independently of cephalothin and cefazoline.</description><subject>Cefamandole - pharmacology</subject><subject>Cefazolin - pharmacology</subject><subject>Cefoxitin - pharmacology</subject><subject>Cephalosporins - pharmacology</subject><subject>Cephalothin - pharmacology</subject><subject>Drug Resistance, Microbial</subject><subject>In Vitro Techniques</subject><subject>Microbial Sensitivity Tests</subject><issn>0300-8126</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1979</creationdate><recordtype>article</recordtype><recordid>eNpjYeA0MDYw0LUwNDLjYOAqLs4yMDAwtTQxZ2dgMzE2t7A052Sw8sxTKMssKcpXKEktLsnMS1fIT1PISy1PLVJITi3ISMzJLy7IL8rMK1bQSCwtycgvUi9WKClKzCvO0eRhYE1LzClO5YXS3Awybq4hzh66BaVJuakp8QVFmbmJRZXxEKuMCUgDAEjuMxA</recordid><startdate>1979</startdate><enddate>1979</enddate><creator>Linzenmeier, G</creator><creator>Rosenthal, E</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>1979</creationdate><title>In vitro testing of newer cephalosporins (author's transl)</title><author>Linzenmeier, G ; Rosenthal, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_4378973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>ger</language><creationdate>1979</creationdate><topic>Cefamandole - pharmacology</topic><topic>Cefazolin - pharmacology</topic><topic>Cefoxitin - pharmacology</topic><topic>Cephalosporins - pharmacology</topic><topic>Cephalothin - pharmacology</topic><topic>Drug Resistance, Microbial</topic><topic>In Vitro Techniques</topic><topic>Microbial Sensitivity Tests</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Linzenmeier, G</creatorcontrib><creatorcontrib>Rosenthal, E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Linzenmeier, G</au><au>Rosenthal, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro testing of newer cephalosporins (author's transl)</atitle><jtitle>Infection</jtitle><addtitle>Infection</addtitle><date>1979</date><risdate>1979</risdate><volume>7 Suppl 2</volume><spage>S225</spage><pages>S225-</pages><issn>0300-8126</issn><abstract>The spectrum of activity of the newer cephalosporins is considerably wider and includes a number of gram-negative bacteria. Test results using cephalothin as 'class disc' of a class of antibiotics is therefore no longer valid for the newer members. Like cefazoline, all of the above-mentioned antibiotics are more effective against Escherichia coli. Cefuroxin and cefoxitin also display increased effectiveness against Klebsiella, as do cefoxitin against Serratia and indolpositive Proteus species, and cefamandole and cefuroxime against Enterobacter. Cefotaxim is superior to all other agents, as was also demonstrated in our own inhibition zone tests; in addition cefotaxim is effective against Pseudomonas aeruginosa. Since the various pathogens do not exhibit a uniform pattern of resistance to these antibiotics, the four new agents should for the time being be tested independently of cephalothin and cefazoline.</abstract><cop>Germany</cop><pmid>437897</pmid></addata></record>
fulltext fulltext
identifier ISSN: 0300-8126
ispartof Infection, 1979, Vol.7 Suppl 2, p.S225
issn 0300-8126
language ger
recordid cdi_pubmed_primary_437897
source Springer Archives (Through 1996)
subjects Cefamandole - pharmacology
Cefazolin - pharmacology
Cefoxitin - pharmacology
Cephalosporins - pharmacology
Cephalothin - pharmacology
Drug Resistance, Microbial
In Vitro Techniques
Microbial Sensitivity Tests
title In vitro testing of newer cephalosporins (author's transl)
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T01%3A01%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20testing%20of%20newer%20cephalosporins%20(author's%20transl)&rft.jtitle=Infection&rft.au=Linzenmeier,%20G&rft.date=1979&rft.volume=7%20Suppl%202&rft.spage=S225&rft.pages=S225-&rft.issn=0300-8126&rft_id=info:doi/&rft_dat=%3Cpubmed%3E437897%3C/pubmed%3E%3Cgrp_id%3Ecdi_FETCH-pubmed_primary_4378973%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/437897&rfr_iscdi=true